Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy.
We assessed the clinical variables predicting the feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy. Thirty patients aged 15 years or older with refractory partial epilepsy, who had been treated with slow-release carbamazepine as monotherapy or in combination therapy, were switched overnight from slow-release carbamazepine (mean dose at switching, 900 mg/day) to oxcarbazepine. Of these 30 patients, 29 (96.7%) had been treated with a slow-release formulation of carbamazepine. The proportion of patients with polytherapy was 85.3%. Overall, 9 of 30 (30%) switched patients experienced clinically significant adverse events until 2 weeks after switching, including 2 with seizure aggravation. The only clinical variable related to the failure of overnight switching was the number of seizures at baseline.
Department of Neurology, University of Ulsan, Seoul, Republic of Korea.
Sang-Ahm
SA
Lee
Kyoung
K
Heo
Won-Joo
WJ
Kim
Hong-Ki
HK
Song
Sung-Eun
SE
Kim
Sang-Ho
SH
Kim
Soon-Kee
SK
No
Byung-In
BI
Lee
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004351:Drug Resistance; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D005544:Forecasting; D006801:Humans; D007723:Korea; D008297:Male; D000078330:Oxcarbazepine; D012640:Seizures / Q000453:epidemiology / Q000517:prevention & control; D017211:Treatment Failure
D000927:Anticonvulsants; D003692:Delayed-Action Preparations; D002220:Carbamazepine; D000078330:Oxcarbazepine